des-aspartate-angiotensin I

Des-aspartate-angiotensin I (DAA-I) is a peptide derived from the renin-angiotensin system (RAS), which plays a central role in regulating blood pressure and fluid balance. DAA-I acts as an agonist at the angiotensin AT1 receptor, but unlike angiotensin II, it elicits protective effects that counteract the deleterious actions of angiotensin II. It has been shown to attenuate inflammation, reduce mortality in animal models of radiation injury, and protect against various pathologies where angiotensin II is implicated—including cardiac hypertrophy, myocardial ischemia-reperfusion injury, hyperglycemia/insulin resistance, and inflammatory conditions. The mechanism involves binding to the AT1 receptor and stimulating prostaglandin E2 (PGE2) release, which mediates anti-inflammatory and radioprotective effects[1][3][4]. DAA-I is orally active and has demonstrated efficacy in preclinical models.

Other names

des-aspartate-angiotensin-IDAA-I